Influx of Novel Agents in AML Leads to Role for Up-front Molecular Testing

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

Read the full article here

Related Articles